Global Glutamate Carboxypeptidase 2 Market Size By Type (INO-5150, E-2072), By Application (Prostate Cancer, Neuropathic Pain), By Region, And Segment Forecasts, 2023 to 2032

The Global Glutamate Carboxypeptidase 2 (GCPII) Market was valued at USD 412.7 million in 2023 and is projected to surpass USD 985.3 million by 2031, expanding at a CAGR of 11.4% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of neurological disorders, advancements in biomarker-based diagnostics, and rising interest in GCPII as a therapeutic and diagnostic target in prostate cancer and neurodegenerative diseases. As drug development pipelines increasingly include enzyme-specific inhibitors and imaging agents, the demand for GCPII-targeted solutions is set to surge.

Drivers:

1. Rising Neurological Disorder Incidences:

An increasing number of Alzheimer’s, schizophrenia, and other neurodegenerative disease cases globally is fueling demand for GCPII-targeted diagnostics and therapeutics, as the enzyme plays a critical role in glutamate regulation within the nervous system.

2. Expanding Applications in Oncology:

GCPII (also known as Prostate-Specific Membrane Antigen, PSMA) is highly expressed in prostate cancer, enabling its use in imaging and targeted therapies. The surge in PSMA-targeted radiopharmaceuticals is accelerating GCPII market growth.

3. Advancements in Radiopharmaceuticals and Molecular Imaging:

The ongoing development of PET imaging agents targeting GCPII enhances early detection and monitoring capabilities in both oncology and neurology, contributing to its market expansion.

Restraints:

1. High R&D and Regulatory Costs:

The development of GCPII-targeted drugs and diagnostics involves significant R&D investment, complex regulatory hurdles, and long clinical timelines, limiting rapid commercialization.

2. Limited Awareness in Developing Markets:

Despite promising clinical applications, low awareness and adoption of GCPII-targeted technologies in emerging economies hamper overall market penetration.

Opportunity:

1. Growth in Personalized Medicine:

With the shift towards precision diagnostics and individualized therapies, GCPII-based tools offer high specificity, opening opportunities for tailored treatment in prostate cancer and neurological conditions.

2. Strategic Collaborations and Licensing Deals:

Biotech and pharmaceutical firms are increasingly entering partnerships for co-developing GCPII inhibitors and diagnostics, driving innovation and market access globally.

3. Expansion in Companion Diagnostics:

GCPII’s integration with companion diagnostics is expected to grow alongside targeted therapies, especially in oncology, presenting a lucrative avenue for companies.

Market by System Type Insights:

The Radiopharmaceuticals segment led the GCPII market in 2023, fueled by increased adoption of PSMA-targeted PET imaging for prostate cancer diagnosis and staging. This segment is anticipated to retain its dominance due to regulatory approvals of new imaging agents and growing oncological applications. The Small Molecule Inhibitors segment is also expanding, with promising pipeline candidates progressing through clinical trials aimed at neurodegenerative diseases and cancer therapeutics.

Market by End-Use Insights:

In 2023, the Hospitals & Diagnostic Imaging Centers segment accounted for the largest share, driven by rising imaging procedures for prostate cancer staging and recurrence monitoring. Research Institutes are also gaining momentum, driven by active involvement in early-stage trials and biomarker studies related to GCPII’s role in CNS and oncology drug discovery.

Market by Regional Insights:

North America held the largest share in 2023, attributed to a robust research infrastructure, early adoption of molecular imaging technologies, and a strong biotech pipeline. Meanwhile, Asia-Pacific is projected to witness the fastest growth due to increasing investment in oncology diagnostics, rising healthcare awareness, and expanding clinical trials in countries like China, Japan, and South Korea.

Competitive Scenario:

Prominent players in the Global Glutamate Carboxypeptidase 2 Market include Advanced Accelerator Applications (a Novartis company), Telix Pharmaceuticals, Blue Earth Diagnostics (Bracco Imaging), Endocyte Inc., Progenics Pharmaceuticals, Point Biopharma, Lantheus Holdings, and Sofie Biosciences. These companies are focused on pipeline expansion, strategic collaborations, and regulatory approvals to enhance their global presence.

Scope of Work – Global Glutamate Carboxypeptidase 2 Market

Report Metric Details

Market Size (2023) USD 412.7 Million

Projected Market Size (2031) USD 985.3 Million

CAGR (2023–2031) 11.4%

Market Segments By System Type (Radiopharmaceuticals, Inhibitors), End-Use (Hospitals, Research Institutes), Region

Growth Drivers Rise in neurodegenerative diseases, growing prostate cancer cases, advancements in targeted imaging

Opportunities Expansion of personalized medicine, strategic licensing, rising companion diagnostics adoption

Key Market Developments:

2023: Telix Pharmaceuticals received FDA approval for its PSMA-targeted PET imaging agent, expanding the availability of GCPII diagnostics across U.S. medical centers.

2024: Lantheus Holdings and POINT Biopharma entered into a strategic collaboration to develop next-generation GCPII radioligand therapies for metastatic prostate cancer.

2025: Blue Earth Diagnostics initiated Phase 3 trials for a novel PSMA-targeted imaging agent aimed at early detection of recurrent prostate cancer.

FAQs:

1) What is the current market size of the Global Glutamate Carboxypeptidase 2 Market?

The market was valued at USD 412.7 million in 2023.

2) What is the major growth driver of the Global Glutamate Carboxypeptidase 2 Market?

The major growth driver is the rising incidence of neurological disorders and prostate cancer, fueling demand for GCPII-targeted diagnostics and therapeutics.

3) Which is the largest region during the forecast period in the Global Glutamate Carboxypeptidase 2 Market?

North America is the largest region due to advanced healthcare infrastructure and early adoption of molecular imaging.

4) Which segment accounted for the largest market share in the Global Glutamate Carboxypeptidase 2 Market?

The Radiopharmaceuticals segment held the largest share in 2023.

5) Who are the key market players in the Global Glutamate Carboxypeptidase 2 Market?

Key players include Telix Pharmaceuticals, Blue Earth Diagnostics, Lantheus Holdings, Advanced Accelerator Applications, and Progenics Pharmaceuticals.